secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001437749-26-015753
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia announces FDA alignment on Helix catheter clearance pathways; no safety concerns
--------------------------------------------------------------------------------

- FDA agreed two pathways for Helix marketing clearance: simultaneous with CardiAMP cell therapy approval or DeNovo via follow-on pre-submission.
- FDA raised no concerns on Helix safety data, device performance, or compatibility with general classes of agents.
- FDA's preferred route is simultaneous approval with CardiAMP cell therapy for heart failure.
- BioCardia aims to pursue both pathways to enhance development and commercial partnering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926015753/0001437749-26-015753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926015753/bcda20260508_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer